Study: CBD as Potential Psychosis Treatment
More research is confirming the benefits of CBD. A new study shows the cannabinoid could be used to treat various forms of psychosis.
A review, published in the november 2013 journal „Neuropsychopharmacology“ suggests that CBD could have potential as an alternative antipsychotic treatment.
The review was conducted as a joint effort by researchers from both the United Kingdom and the Netherlands. The review works as a meta-analysis forum, assessing the results of prior pre-clinical and clinical studies conducted by other teams. Their meta-analysis concluded that a substantial proportion of research documents how CBD appears reduce the symptoms of psychosis in both animals and humans, especially in the cases of schizophrenia, Parkinson’s Disease and ketamine-induced psychosis.
Not only this, but human tests also report CBD to be a safe and well tolerated substance for the human body.
The review specifically highlights the findings of one study in its argument. This was a double blind study from 2012 that conducted a randomized placebo controlled trial, assessing the effectiveness of CBD in comparison to prescription antipsychotic drugs in schizophrenic patients with acute paranoia. The study concluded that those who were given CBD exhibited the same level of clinical improvement as those who were given the prescription antipsychotic drugs, but with significantly less side effects.
In conclusion, the review suggests that CBD should be further investigated as a viable antipsychotic treatment. Currently, CBD is recognised as showing anti-inflammatory, anti-diabetic, anti-epileptic and anti-cancer properties.
It is yet another positive entry into the book of CBD, and it is unlikely to be long before we see even more promising findings into the matter.